Gary E. Gallick

17.8k total citations · 3 hit papers
202 papers, 13.7k citations indexed

About

Gary E. Gallick is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gary E. Gallick has authored 202 papers receiving a total of 13.7k indexed citations (citations by other indexed papers that have themselves been cited), including 116 papers in Molecular Biology, 100 papers in Oncology and 38 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gary E. Gallick's work include PI3K/AKT/mTOR signaling in cancer (25 papers), Prostate Cancer Treatment and Research (25 papers) and Bone health and treatments (22 papers). Gary E. Gallick is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (25 papers), Prostate Cancer Treatment and Research (25 papers) and Bone health and treatments (22 papers). Gary E. Gallick collaborates with scholars based in United States, Spain and Taiwan. Gary E. Gallick's co-authors include Nila U. Parikh, Lee M. Ellis, Justin M. Summy, James L. Abbruzzese, Wenbiao Liu, Douglas B. Evans, Huamin Wang, Serk In Park, Ami N. Shah and David J. McConkey and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Gary E. Gallick

202 papers receiving 13.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer

2009 729 citations Thiruvengadam Arumugam, Vijaya Ramachandran et al. Cancer Research profile →
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571

2002 529 citations Ji Yuan Wu, Gary E. Gallick et al. profile →
Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway

2009 527 citations James L. Abbruzzese, Gary E. Gallick et al. Cancer Research profile →

Peers

Countries citing papers authored by Gary E. Gallick

Since Specialization

Citations

This map shows the geographic impact of Gary E. Gallick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary E. Gallick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary E. Gallick more than expected).

Fields of papers citing papers by Gary E. Gallick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary E. Gallick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary E. Gallick. The network helps show where Gary E. Gallick may publish in the future.

Co-authorship network of co-authors of Gary E. Gallick

This figure shows the co-authorship network connecting the top 25 collaborators of Gary E. Gallick. A scholar is included among the top collaborators of Gary E. Gallick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary E. Gallick. Gary E. Gallick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cabozantinib Reverses Renal Cell Carcinoma–mediated Osteoblast Inhibition in Three-dimensional Coculture In Vitro and Reduces Bone Osteolysis In Vivo 2020 ·Molecular Cancer Therapeutics ·Tianhong Pan, (unknown), Kelsea M. Hubka, Jian H. Song, Song-Chang Lin, Guoyu Yu, Yu-Chen Lee, Gary E. Gallick, Shi‐Ming Tu, Daniel A. Harrington, Mary C. Farach‐Carson, Sue-Hwa Lin, Robert L. Satcher	11
2	Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFβRIII–p38MAPK–pS249/T252RB Pathway 2018 ·Cancer Research ·Li‐Yuan Yu‐Lee, Guoyu Yu, Yu‐Chen Lee, Song-Chang Lin, Jing Pan, Tianhong Pan, Kai‐Jie Yu, Bin Liu, Chad J. Creighton, Jaime Rodriguez‐Canales, Pamela Villalobos, Ignacio I. Wistuba, Eulàlia de Nadal, Francesc Posas, Gary E. Gallick, Sue-Hwa Lin	126
3	Organelle-Derived Acetyl-CoA Promotes Prostate Cancer Cell Survival, Migration, and Metastasis via Activation of Calmodulin Kinase II 2018 ·Cancer Research ·Guoyu Yu, Chien-Jui Cheng, Song-Chang Lin, Yu-Chen Lee, Daniel E. Frigo, Li‐Yuan Yu‐Lee, Gary E. Gallick, Mark Titus, Leta K. Nutt, Sue-Hwa Lin	30
4	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer 2017 ·Clinical Cancer Research ·Christine M. Parseghian, Nila U. Parikh, Ji Yuan Wu, Zhi-Qin Jiang, Laura E. Henderson, Feng Tian, Brice Pastor, Marc Ychou, Kanwal Raghav, Arvind Dasari, David R. Fogelman, Αναστασία Κατσιαμπούρα, David G. Menter, Robert A. Wolff, Cathy Eng, Michael J. Overman, Alain R. Thierry, Gary E. Gallick, Scott Kopetz	47
5	A ROR1–HER3–lncRNA signalling axis modulates the Hippo–YAP pathway to regulate bone metastasis 2017 ·Nature Cell Biology ·Chunlai Li, Shouyu Wang, Zhen Xing, Aifu Lin, Ke Liang, Jian H. Song, Qingsong Hu, Jun Yao, Zhongyuan Chen, Peter K. Park, David H. Hawke, Jianwei Zhou, Yan Zhou, Shuxing Zhang, Han Liang, Mien‐Chie Hung, Gary E. Gallick, Leng Han, Chunru Lin, Liuqing Yang	246
6	Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer 2015 ·Clinical Cancer Research ·Andreas Varkaris, Paul G. Corn, Nila U. Parikh, Eleni Efstathiou, Jian H. Song, Yu-Chen Lee, Ana M. Aparicio, Anh Hoang, Sanchaika Gaur, (unknown), Sankar N. Maity, (unknown), Bogdan Czerniak, Yiping Shao, Mian M. Alauddin, Sue-Hwa Lin, Christopher J. Logothetis, Gary E. Gallick	37
7	Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer 2015 ·Cancer Research ·Yu-Chen Lee, Song-Chang Lin, Guoyu Yu, Chien-Jui Cheng, Bin Liu, Hsuan‐Chen Liu, David H. Hawke, Nila U. Parikh, Andreas Varkaris, Paul G. Corn, Christopher J. Logothetis, Robert L. Satcher, Li‐Yuan Yu‐Lee, Gary E. Gallick, Sue-Hwa Lin	36
8	The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK+ T-cell lymphoma 2015 ·Molecular Cancer ·Deeksha Vishwamitra, Choladda V. Curry, Serhan Alkan, Yao-Hua Song, Gary E. Gallick, Ahmed O. Kaseb, Ping Shi, Hesham M. Amin	22
9	RSK Promotes Prostate Cancer Progression in Bone through ING3, CKAP2, and PTK6-Mediated Cell Survival 2014 ·Molecular Cancer Research ·Guoyu Yu, Yu-Chen Lee, Chien-Jui Cheng, (unknown), Jian H. Song, Gary E. Gallick, Li‐Yuan Yu‐Lee, Jian Kuang, Sue-Hwa Lin	42
10	Inhibition of Cell Adhesion by a Cadherin-11 Antibody Thwarts Bone Metastasis 2013 ·Molecular Cancer Research ·Yu-Chen Lee, Mehmet Asım Bilen, Guoyu Yu, Song-Chang Lin, Chih‐Fen Huang, Angélica Ortiz, Hyojin Cho, Jian H. Song, (unknown), Jian Kuang, Gary E. Gallick, Li‐Yuan Yu‐Lee, (unknown), Sue-Hwa Lin	35
11	Colorectal Adenoma Stem-like Cell Populations: Associations with Adenoma Characteristics and Metachronous Colorectal Neoplasia 2013 ·Cancer Prevention Research ·Angela N. Bartley, Nila U. Parikh, Chiu‐Hsieh Hsu, Denise J. Roe, Julie A. Buckmeier, Lynda Corley, (unknown), Gary E. Gallick, Peter Lance, Patricia A. Thompson, Stanley R. Hamilton	10
12	Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents 2012 ·Clinical Cancer Research ·Muling Mao, Feng Tian, John M. Mariadason, Chun C. Tsao, Robert Lemos, Farshid Dayyani, Y.N. Vashisht Gopal, Zhi-Qin Jiang, Ignacio I. Wistuba, Xi Tang, William G. Bornman, Gideon Bollag, Gordon B. Mills, Garth Powis, Jayesh Desai, Gary E. Gallick, Michael A. Davies, Scott Kopetz	235
13	BMP4 Promotes Prostate Tumor Growth in Bone through Osteogenesis 2011 ·Cancer Research ·Yu-Chen Lee, Chien-Jui Cheng, Mehmet Asım Bilen, (unknown), Robert L. Satcher, Li‐Yuan Yu‐Lee, Gary E. Gallick, Sankar N. Maity, Sue-Hwa Lin	109
14	Functional Roles of Src and Fgr in Ovarian Carcinoma 2011 ·Clinical Cancer Research ·Hye‐Sun Kim, Hee Dong Han, Guillermo N. Armaiz-Peña, Rebecca L. Stone, Eun Ji Nam, Jeong‐Won Lee, Mian M.K. Shahzad, Alpa M. Nick, Sun Joo Lee, Ju‐Won Roh, Masato Nishimura, Lingegowda S. Mangala, Justin Bottsford-Miller, Gary E. Gallick, Gabriel Lopez‐Berestein, Anil K. Sood	62
15	Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer breakdown → 2009 ·Cancer Research ·Thiruvengadam Arumugam, Vijaya Ramachandran, Keith F. Fournier, Huamin Wang, Lauren Marquis, James L. Abbruzzese, Gary E. Gallick, Craig D. Logsdon, David J. McConkey, Woonyoung Choi	729
16	Sustained Src Inhibition Results in Signal Transducer and Activator of Transcription 3 (STAT3) Activation and Cancer Cell Survival via Altered Janus-Activated Kinase–STAT3 Binding 2009 ·Cancer Research ·Banibrata Sen, Babita Saigal, Nila U. Parikh, Gary E. Gallick, Faye M. Johnson	100
17	Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells Is Mediated by Oxidative Stress 2009 ·Cancer Research ·Scott Kopetz, Donald P. Lesslie, (unknown), Serk In Park, (unknown), Nila U. Parikh, Michael P. Kim, James L. Abbruzzese, Lee M. Ellis, Joya Chandra, Gary E. Gallick	127
18	Src Continues Aging: Current and Future Clinical Directions 2007 ·Clinical Cancer Research ·Scott Kopetz, Ami N. Shah, Gary E. Gallick	91
19	Src Family Nonreceptor Tyrosine Kinases as Molecular Targets for Cancer Therapy 2007 ·Anti-Cancer Agents in Medicinal Chemistry ·Faye M. Johnson, Gary E. Gallick	80
20	Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma 2006 ·Cancer Research ·Liz Y. Han, Charles N. Landen, José G. Treviño, Jyotsnabaran Halder, Yvonne G. Lin, Aparna A. Kamat, Tae‐Jin Kim, William M. Merritt, Robert L. Coleman, David M. Gershenson, William C. Shakespeare, Yihan Wang, (unknown), Chester A. Metcalf, David C. Dalgarno, Tomi K. Sawyer, Gary E. Gallick, Anil K. Sood	68

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact